ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncology Group study
Keyword(s):
2013 ◽
Vol 2013
◽
pp. 1-4
◽
2015 ◽
Vol 23
(6)
◽
pp. 505-508
◽